a) purifying a population of non-covalently associated stress protein-peptide complexes from mammalian tumor cells;

b) releasing the peptides from said population of complexes; and

c) recovering the released population of peptides.

B2 Cont'd. Sub C1

20. (New) A purified peptide that is present as a non-covalent complex with a stress protein in a mammalian tumor cell.

21. (New) A purified peptide consisting of the amino acid sequence of a peptide that is present as a non-covalent complex with a stress protein in a mammalian tumor cell.

22. (New) The composition of claim 19 further comprising a cytokine.

23. (New) The composition of claim 22 wherein said cytokine is selected from the group consisting of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IFNα, IFNβ, IFNγ, TNF∝, TNFβ, G-CSF, GM-CSF, and TGF-β.

24. (New) The composition of claim 19 wherein the peptides are released from said population of complexes by a method comprising placing said population of complexes in the presence of adenosine triphosphate, low pH, or both.

25. (New) The composition of claim 19, wherein said mammalian tumor cells are human cells.

26. (New) The composition of claim 19 wherein said mammalian tumor cells are from a tumor selected from the group consisting of melanocarcinoma, hepatocarcinoma, and renal cell carcinoma.

27. (New) The composition of claim 19 wherein said tumor cells are from a metastasis.

28. (New) The composition of claim 19, wherein said tumor cells have been proliferated in vivo.

29. (New) The composition of claim 19, wherein said tumor cells have been proliferated in vitro.

B2 Cont'd.

30. (New) The composition of claim 19, wherein the stress protein is a member of a stress protein family selected from the group consisting of hsp60, hsp70, and hsp90.

31. (New) The composition of claim 19, wherein the stress protein is gp96.

32. (New) The peptide of claim 20 or 21, wherein said mammalian tumor cell is a human cell.

33. (New) The peptide of claim 20 or 21 wherein said mammalian tumor cell is from a tumor selected from the group consisting of melanocarcinoma, hepatocarcinoma, and renal cell carcinoma.

34. (New) The peptide of claim 20 or 21, wherein said tumor cell is from a metastasis.

35. (New) The peptide of claim 20, wherein said tumor cell has been proliferated in vivo.

36. (New) The peptide of claim 21, wherein said tumor cell has been proliferated in vitro.

37. (New) The peptide of claim 20 or 21, wherein the stress protein is a member of a stress protein family selected from the group consisting of hsp60, hsp70, and hsp90.

38. (New) The peptide of claim 20 or 21, wherein the stress protein is gp96.

39. (New) A method of making a composition comprising a population of peptides comprising:

a) purifying a population of stress protein-peptide complexes from mammalian tumor cells;

b) releasing a population of peptides from said population of complexes; and

c) recovering the released population of peptides.

40. (New) A method of making a purified peptide comprising:

a) purifying a population of stress protein-peptide complexes from mammalian tumor cells;

b) releasing a population of peptides from said population of complexes; and

c) purifying a peptide from the released population of peptides.

41. (New) The method of claim 39 wherein the peptides are released from said population of complexes by a method comprising placing said population of complexes in the presence of adenosine triphosphate, low pH, or both.

42. (New) The method of claim 40 wherein the peptides are released from said population of complexes by a method comprising placing said population of complexes in the presence of adenosine triphosphate, low pH, or both.

43. (New) The method of claim 39 or 40 wherein said mammalian tumor cells are human cells.

44. (New) The method of claim 39 or 40, wherein said mammalian tumor cells are from a tumor selected from the group consisting of melanocarcinoma, hepatocarcinoma, and renal cell carcinoma.

45. (New) The method of claim 39 or 40, wherein said mammalian tumor cells are from a metastasis.

46. (New) The method of claim 39 or 40, wherein said mammalian tumor cells have been proliferated in vitro.

47. (New) The method of claim 39 or 40, wherein said mammalian tumor cells have been proliferated in vivo.

48. (New) The method of claim 39 or 40, wherein the stress protein is a member of a stress protein family selected from the group consisting of hsp60, hsp70, and hsp90.

49. (New) The method of claim 39 or 40, wherein the stress protein is gp96.

50. (New) A composition comprising the purified peptide of claim 20 or 21 and a cytokine.

51. (New) The composition of claim 50 wherein said cytokine is selected from the group consisting of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IFNα, IFNβ, IFNγ, TNF∝, TNFβ, G-CSF, GM-CSF, and TGF-β.

REMARKS

The title of the application has been amended to better reflect the claimed subject matter.

Claims 2-18 have been canceled without prejudice, and new claims 19-51 added, to more particularly point out and distinctly claim that which Applicant regards as the invention. The subject matter of the new claims is fully supported in the specification. In particular, support for the new claims is found in the specification as set forth in the chart below. No new matter is introduced.